Palvella Posts $24.6M Q3 Loss, $236.7M Cash Ahead of Feb 2027 PDUFA
PVLA has more than doubled off its 52-week low of $71.55 on elevated volume (1.8× avg).
Summary
Palvella burned $24.6 million in Q3, up from $11.3 million a year ago, as R&D jumped to $10.8 million and G&A nearly quadrupled to $11.9 million on launch and public-company costs, producing a loss of $1.70 per share. It ended September with $236.7 million in cash and short-term investments, down modestly from $250.6 million at mid-year, which funds the planned standalone U.S. commercial launch in the first half of 2027 if QTORIN rapamycin is approved. The FDA accepted the NDA and granted Priority Review with a February 28, 2027 PDUFA date, the central binary for the stock. Pipeline timing held: Phase 3 cutaneous venous malformation trial starts in Q4 2026, Phase 2 DSAP trial starts in Q4 2026, and two additional programs will be announced by year-end. The company also named James R. Treat, M.D. Chief Medical Officer effective December 21, 2026.
At the time of this announcement, PVLA was trading at $153.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $71.55 to $163.75. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.